CD3+/CD16+CD56+cell numbers in peripheral blood are correlated with higher tumor burden in patients with diffuse large B-cell lymphoma

Folia Histochemica et Cytobiologica

Volumn 49, Issue 1, 2011, Pages 183-187

  Hus, Iwona ^a   Starosławska, Elzbieta ^b   Bojarska Junak, Agnieszka ^a   Dobrzyńska Rutkowska, Aneta ^b   Surdacka, Agata ^a   Wdowiak, Paulina ^a   Wasiak, Magdalena ^a   Kusz, Maria ^a   Twardosz, Anna ^b   Dmoszyńska, Anna ^a   Roliński, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Centrum Onkologii Ziemi Lubelskiej   (Poland)

Author keywords

Anti tumor immunity; Diffuse large B cell lymphoma

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CD16+ CD56+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MALE; NATURAL KILLER T CELL; T LYMPHOCYTE; TUMOR VOLUME;

EID: 79958126730     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0025     Document Type: Article

References (25)

1. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf. 2009; 8: 223-235.
2. Kahl B. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma. Semin Hematol. 2008; 5:90-94.
3. Mercer JC, Ragin MJ, August A. Natural killer T cells: rapid responders controlling immunity and disease. Int J Biochem Cell Biol. 2005; 37: 1337-1343.
4. Golden-Mason L, Castelblanco N, O'Farrelly C, Rosen HR. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol. 2007; 81: 9292-9298.
5. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d--restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol. 2008; 20: 358-368.
6. Brossay L, Chioda M, Burdin N et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med. 1998; 188: 1521-1528
7. Spada FM, Koezuka Y, Porcelli SA et al. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med. 1998;188:1529-1534.
8. + natural T cells with distinct cytotoxic activities and Th1, Th2 and Th0 cytokine secretion patterns. J Immunol. 1999; 163: 2314-2321.
9. Molling JW, Moreno M, van der Vliet HJ et al. Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol. 2008; 129: 182-194.
10. Wallace ME, Smyth MJ. The role of natural killer cells in tumor control -effectors and regulators of adaptive immunity. Springer Semin Immunopathol. 2005; 27: 49-64.
11. Berzofsky JA, Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol. 2008; 180: 3627-3635.
12. Dhodapkar MV. Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Front Biosci. 2009; 14: 796-807.
13. Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci. 2000; 99: 638-645.
14. Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci. 2006; 97: 807-812.
15. Kawano T, Nakayama T, Kamada N et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 1999; 59: 5102-5105.
16. Schwemmer B. Natural killer T cells in patients with prostatic carcinoma. Urol Int. 2003; 71: 146-149.
17. Tahir SM, Cheng O, Shaulov A. et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol. 2001; 167: 4046-4050.
18. Motohashi S, Kobayashi S, Ito T. et al. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Int J Cancer. 2002; 102: 159-165.
19. Yanagisawa K, Seino K, Ishikawa Y, Nozue M, Todoroki T, Fukao K. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol. 2002; 168: 6494-6499.
20. Konishi J, Yamazaki K, Yokouchi H, Shinagawa N, Iwabuchi K, Nishimura M. The characteristics of human NKT cells in lung cancer - CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Hum Immunol. 2004; 65: 1377-1388.
21. + NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer. 2005; 116: 87-93.
22. + NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk Res. 2005; 29: 147-152.
23. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood. 2008; 111: 5637-5645.
24. Bagnara D, Ibatici A, Corselli M et al. Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms. Haematologica. 2009; 94: 967-974.
25. Guven H, Gilljam M, Chambers BJ et al. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunothera-py. Leukemia. 2003; 17: 1973-1980.